Details
Stereochemistry | MIXED |
Molecular Formula | C24H33NO3.C6H8O7 |
Molecular Weight | 575.6472 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CC(O)(CC(O)=O)C(O)=O.CCN(CC)CCOC(=O)C(CC1CCCO1)CC2=C3C=CC=CC3=CC=C2
InChI
InChIKey=LKLQMEYKQKAQCX-UHFFFAOYSA-N
InChI=1S/C24H33NO3.C6H8O7/c1-3-25(4-2)14-16-28-24(26)21(18-22-12-8-15-27-22)17-20-11-7-10-19-9-5-6-13-23(19)20;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-7,9-11,13,21-22H,3-4,8,12,14-18H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
DescriptionCurator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/1369714
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/1369714
Naftidrofuryl (INN), also known as nafronyl or as the oxalate salt naftidrofuryl oxalate or nafronyl oxalate, is a vasodilator used in the management of peripheral and cerebral vascular disorders. The drug act as a selective antagonist of 5-HT2 receptors. Naftidrofuryl is marketed under a variety of trade names, including Artocoron, Azunaftil, Di-Actane, Dusodril, Enelbin, Frilix, Gevatran, Iridus, Iridux, Luctor, Nafti, Naftoling, Naftodril, Nafoxal, Praxilene, Sodipryl retard, and Vascuprax. Praxilene belongs to a group of medicines known as ‘metabolic activators’. These are used to treat different types of blood circulation problems. Praxilene allows the body to make better use of the oxygen in your blood. Praxilene is used to treat the following symptoms: cramp-like pains; cramps in legs at night; severe pain in r legs when people are resting (rest pain); pale or blue fingers or toes which get worse when it is cold; numbness, tingling or burning feelings in the fingers or toes (Raynaud’s syndrome or acrocyanosis); open sores on the legs or feet (trophic ulcers); poor circulation caused by diabetes (diabetic arteriopathy).
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095200 Sources: http://www.ncbi.nlm.nih.gov/pubmed/1369714 |
0.06 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Praxilene Approved UseUnknown Launch Date2016 |
PubMed
Title | Date | PubMed |
---|---|---|
Naftidrofuryl oxalate, nootropic effects on the scopolamine- and the basal forebrain lesion-induced amnesia in rats. | 1991 Aug |
|
Behavioral studies of the effects of moderate oligemic hypoxia caused by bilateral clamping of carotid arteries in mice. Impairment of spatial working memory. | 1998 Jul-Oct |
|
[Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication]. | 2001 Apr |
|
New treatment options in intermittent claudication: the US experience. | 2001 Apr |
|
Naftidrofuryl in the treatment of vascular dementia. | 2001 Dec |
|
[Deleterious cardiac effects of serotonin in myocardial ischemia: role of naftidrofuryl]. | 2001 Jun |
|
A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS). | 2001 Mar |
|
Inhibition of purified pig and human liver retinyl ester hydrolase by pharmacologic agents. | 2001 May |
|
Treatment alternatives for nocturnal leg cramps. | 2001 May 21 |
|
Pharmacotherapy of intermittent claudication. | 2001 Nov |
|
[Current EMNID survey on peripheral arterial occlusive disease]. | 2002 |
|
Effect of naftidrofuryl on intramuscular partial oxygen pressure (pO2) prior to, during and after physical load on the treadmill in apparently healthy subjects. | 2002 |
|
Reduction of endothelin-1 binding and inhibition of endothelin-1-mediated detrusor contraction by naftidrofuryl. | 2002 Aug |
|
Vitamin A metabolism is altered in brown Norway and long-Evans rats infused with naftidrofuryl or erythromycin intravenously. | 2002 Jul |
|
Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program. | 2002 Mar |
|
[Application of prostaglandin E1 and Naftidrofuryl in combined treatment of purulent-necrotic complications of the diabetic foot syndrome]. | 2002 Nov-Dec |
|
Nocturnal leg cramps in older people. | 2002 Oct |
|
Naftidrofuryl-induced liver injury. | 2003 Jun |
|
Calcium oxalate deposition in renal allografts: morphologic spectrum and clinical implications. | 2004 Aug |
|
[Secondary prevention and conservative therapy of obliterative arteriosclerosis]. | 2004 May 16 |
|
Acral necrosis after inadequate excessive administration of bleomycin in a testicular cancer patient. | 2005 Jan |
|
[Vasoactive agents and prostanoids in the therapy of PAD: facts, questions, disproven assumptions]. | 2006 Aug |
|
[Inpatient infusion treatment for acute tinnitus with and without adjuvant psychotherapeutic intervention. A comparison of psychological effectiveness]. | 2006 Oct |
|
Peripheral arterial disease in the elderly. | 2007 |
|
Naftidrofuryl for acute stroke. | 2007 Apr 18 |
|
A novel inhibitor of Mycobacterium tuberculosis pantothenate synthetase. | 2007 Feb |
|
Management of peripheral arterial disease in the elderly: focus on cilostazol. | 2008 |
|
Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data. | 2009 Mar 10 |
|
Current approach to the diagnosis and treatment of femoral-popliteal arterial disease. A systematic review. | 2009 Nov |
|
Muscle cramps: quinine derivatives likely to be effective but not recommended for routine use due to toxicity; vitamin B complex, naftidrofuryl and calcium channel blockers possibly effective. | 2010 Aug |
Patents
Sample Use Guides
The recommended dose is one or two capsules (100 mg naftidrofuryl oxalate) three times a day, for a minimum of three months
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7863151
After culture in a rat serum enriched with naftidrofuryl at concentration of 20 uM, we observed a protective effect of this drug toward the disruption of axonal microtubules by vinka alkaloids
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
286-639-8
Created by
admin on Sat Dec 16 09:40:58 GMT 2023 , Edited by admin on Sat Dec 16 09:40:58 GMT 2023
|
PRIMARY | |||
|
184479
Created by
admin on Sat Dec 16 09:40:58 GMT 2023 , Edited by admin on Sat Dec 16 09:40:58 GMT 2023
|
PRIMARY | |||
|
85293-34-1
Created by
admin on Sat Dec 16 09:40:58 GMT 2023 , Edited by admin on Sat Dec 16 09:40:58 GMT 2023
|
PRIMARY | |||
|
1BB8I7MT98
Created by
admin on Sat Dec 16 09:40:58 GMT 2023 , Edited by admin on Sat Dec 16 09:40:58 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD